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Abstract
Background: Pancratistatin (PST), a compound extracted from an Amaryllidaceae (AMD) family
plant, has been shown to specifically induce apoptosis in cancer cells with no/minimal toxic effect
on normal cells. A systematic synthetic approach has indicated that the minimum cytotoxic
pharmacophore comprises the trans-fused b/c-ring system containing the 2, 3, 4-triol unit in the C-
ring. To further explore the structure-activity relationship of this group of compounds we have
investigated the anti-cancer efficacy and specificity of two PST-related natural compounds, AMD4
and AMD5. Both of these compounds lack the polyhydroxylated lycorane element of PST instead
having a methoxy-substuituted crinane skeleton.
Results: Our results indicate that AMD5 has efficacy and selectivity similar to PST, albeit at a 10-
fold increased concentration. Interestingly AMD4 lacks apoptotic activity.
Conclusion: Our results indicate that the phenanthridone skeleton in natural Amaryllidaceae
alkaloids may be a significant common element for selectivity against cancer cells; furthermore, the
configuration of the methoxy-side groups is responsible for higher binding affinity to the target
protein/s thus making for a more efficient anti-cancer agent.
Background
The initial report by Pettit and colleagues in 1993 demon-
strated that Pancratistatin (PST) a natural compound iso-
lated from the Hawaiian spider lily (Hymenocallis littoralis)
displayed potent cytotoxicity against human tumour cell
lines [1]. They also noted that in the NCI "disease ori-
ented" in vitro anti-tumour screen against 60 cell lines rep-
resenting lung, colon, ovarian, renal, brain, melanoma
and myelocytic leukemia, the pattern of PST's activity
against the various tumour types was distinct from that of
other known anti-tumour drug classes. Recently, we dem-
onstrated the selective toxicity of PST to cancer cells and
the sparing of normal cells at micromolar doses [2]. In
addition we have demonstrated that PST acts by affecting
mitochondrial function and inducing apoptosis in malig-
nant cell lines [3].
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A systematic synthetic approach has been used to deter-
mine the minimum cytotoxic pharmacophore and is
known to comprise the trans-fused b/c-ring system con-
taining the 2, 3, 4-triol unit in the C-ring [4-6]. It has also
been noted that the 2, 3-diol derivatives have significant
activity [7], indicating that the C3-hydroxyl is a moderat-
ing influence. The C7 phenolic and C1 hydroxyl functions
are not essential [8,9].
The aim of present work was to further evaluate the struc-
ture-activity relationships of two other AMD alkaloids,
AMD4 and AMD5 (Figure 1). Both these compounds lack
the multiple hydroxyl groups but instead have a methoxy
group that varies in orientation between AMD4 (α) and
AMD5 (β). Our results indicated that like PST, AMD5 has
the capability of selectively inducing apoptosis in cancer
cells while sparing normal cells, albeit at a concentration
10-fold higher.
Results
Amaryllidaceae alkaloids induce apoptosis in Jurkat cells
Jurkat cells were incubated with different concentrations
of AMD4 and AMD5 for up to 72 hrs. The degree of apop-
tosis resulting from treatment was observed by Hoechst
staining where condensed, brightly stained nuclei indi-
cated apoptotic cell death. The number of apoptotic
nuclei was expressed as a percentage of the total number
of cells in a dose-dependent manner; alkaloid AMD5 at a
concentration of 10 μM incited apoptosis in over 40% of
Jurkat cells after 48 hrs and was the working concentration
used for further experiments (Figures 2 &3A). In contrast
to this finding, alkaloid AMD4 had a minimal effect on
cancer cell viability under similar treatment conditions.
To compliment Hoechst staining, the Annexin-V assay
was carried out at several time-points in order to monitor
phosphatidylserine flipping to the outer leaflet of the
plasma membrane, a characteristic apoptotic event. As
previously reported, Annexin-V staining is specific to
apoptotic cells, and background staining is low in unaf-
fected cells [11]. Jurkat cells incubated with 10 μM AMD5
resulted in a high incidence of phosphatidylserine flip;
approximately 45% of Jurkat cells were observed to be
labeled with Annexin-V-FITC (Figure 3B). Necrotic death
in Jurkat cells after similar treatment times with either
alkaloid was not observed by Trypan-blue staining, sug-
gesting that cell death is apoptotic only (data not shown).
DNA fragmentation observed in Jurkat cells treated with 
Amaryllidaceae alkaloids
The TUNEL (terminal transferase dUTP nick end labeling)
assay was used to measure the extent of DNA fragmenta-
tion that occurs following treatment with alkaloid AMD5.
Cells were grown and treated at 10 μM final concentration
for 24 hrs. At this time-point, approximately 20% of cells
displayed characteristic apoptotic morphology with
Hoechst staining. As shown in figure 4, extensive DNA
fragmentation was visible by fluorescence microscopy in
cells treated with AMD5; this corresponds with the
increase in apoptotic morphology at 48 hrs of treatment
with this alkaloid.
Amaryllidaceae alkaloid AMD5 causes early activation of 
caspase-3; disruption of the mitochondrial membrane 
potential delayed
The role of caspases as molecular mediators of apoptosis
was examined after treatment up to 48 hrs with these alka-
loids. A slight increase in caspase-3 activation was
observed after 6 hrs in Jurkat cells treated with AMD4;
however, a more drastic increase of 3 fold over control was
incited after a 3 hr treatment with AMD5 (Figure 5A). At
later treatment times of 24 and 48 hrs, caspase-3 activity
reduced as found by the Mito-Casp assay (data not
shown). This assay detects activation of caspases-3, -7 and
-9 (executioner caspases) and also measures a change in
mitochondrial membrane potential. Our results show
that after 48 hrs the mitochondrial membrane potential
has destabilized in correspondence with an increased
number of apoptotic cells (Figure 5B). Destabilization of
the mitochondrial membrane potential indicates leakage
of cytotoxic mitochondrial contents into the cytoplasm,
initiating the cell death process.
Normal nucleated blood cells are unaffected by treatment 
with Amaryllidaceae alkaloid AMD5
Mononuclear cells from peripheral venous blood were
purified by centrifugation at 2900 rpm for 30 min at 37°C
from whole blood obtained from a healthy volunteer. The
cells were treated with 10 μM of AMD5 for 48 hrs, and
then stained with Hoechst dye to observe apoptotic mor-
phology. As shown in figure 6, this alkaloid had minimal
effect on the viability of normal nucleated blood cells in
comparison to untreated cells. This result suggests that
AMD5 may be less toxic to healthy cells at a dosage capa-
ble of inducing apoptosis in approximately 45% of can-
cerous Jurkat cells after 48 hrs. As the effect of AMD4
against Jurkat cells was minimal, the specificity of this
alkaloid was not tested against normal nucleated blood
cells for specificity.
Discussion
Here we observe that AMD5, a natural alkaloid from the
Amaryllidaceae family, is capable of inducing apoptosis in
more than 40% of Jurkat cells at a 10 μM concentration
after 48 hrs treatment. In addition, this alkaloid was
observed to have low toxicity to healthy mono-nucleated
blood cells after 48 hrs treatment. This result suggests that
crinane-type  Amaryllidaceae  alkaloids may possess anti-
cancer activity similar to the lycorane derivatives related to
PST. PST has been shown to be a highly specific anti-can-
cer agent, able to induce apoptosis in over 90% of JurkatCancer Cell International 2007, 7:10 http://www.cancerci.com/content/7/1/10
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cells in only 24 hrs at 1 μM final concentration [11,14,15].
It appears that a correctly functionalized phenanthridone
core may thus be a common minimal structural require-
ment for these cell specific anti-cancer agents. Although
AMD5 was found to be well tolerated in non-cancerous
cell lines in a cell culture model, its effects on physiologi-
cal parameters in animal models should be evaluated for
pharmacokinetic studies to determine the adsorption, dis-
tribution, metabolism, excretion and toxic properties.
An early increase in caspase-3 activation upon treatment
with AMD5 suggests that an extrinsic pathway of apopto-
sis may be stimulated by this alkaloid. Our study also
found that mitochondrial membrane potential was dis-
rupted after 48 hrs, when over 40% of cells were apop-
totic. This indicates that the intrinsic pathway of
apoptosis, by which cytochrome c release from the mito-
chondria leads to a cascade of events that activates cas-
pase-3 downstream, may not become activated. In
comparison with AMD5, AMD4 had minimal effect
against cancerous cells, which may indicate that the posi-
tion of the methoxy side-group is crucial. AMD5, with the
β-methoxy configuration, may have a stronger interaction
with a critical protein versus AMD4, whose functional
group is in the alpha configuration. This difference may
account for our finding that AMD5 is a more efficient
inducer of apoptosis in Jurkat cells than AMD4. It must be
noted that the addition of an oxymethyl group has been
A. Dose-response curve for Jurkat cells treated with various concentrations of either AMD4 or AMD5 for 48 hrs Figure 2
A. Dose-response curve for Jurkat cells treated with various concentrations of either AMD4 or AMD5 for 48 
hrs. Cells were stained with cell-permeable Hoechst 33342 dye; brightly stained and condensed nuclei were considered to be 
apoptotic while non-bright, smooth nuclei were considered healthy (non-apoptotic). The degree of apoptosis was calculated by 
the number of apoptotic cells counted over the total number of cells visible and displayed as a percentage. A minimum of 5 
fields with at least 100 cells per field were counted and tabulated using Microsoft Excel software; values that are statistically sig-
nificant to p < 0.05 are indicated with an asterisk. Micromolar is represented as uM in this figure only. B. Time Course: A 
measurement of the degree of apoptosis induced in Jurkat cells treated with 10 μM of either AMD4 or AMD5 
over 72 hours. Following treatment, Jurkat cells were incubated with cell-permeable Hoechst 33342 dye; brightly stained 
condensed nuclei were considered to be apoptotic while non-bright, smooth nuclei were considered healthy. The degree of 
apoptosis was calculated by the number of apoptotic cells counted over the total number of cells visible displayed as a percent-
age. A minimum of 5 fields with at least 100 cells per field were counted and tabulated using Microsoft Excel software; values 
that are statistically significant to p < 0.05 are indicated with an asterisk.
Chemical structure of native Pancratistatin (A) and of Ama- ryllidaceae alkaloids AMD4 and AMD5 (B) Figure 1
Chemical structure of native Pancratistatin (A) and 
of Amaryllidaceae alkaloids AMD4 and AMD5 (B). 
The phenanthridone skeleton is a conserved feature in alka-
loids of the Amaryllidaceae family. The Amaryllidaceae com-
pounds have a methoxy group that varies in orientation 
between AMD4 (α) and AMD5 (β).Cancer Cell International 2007, 7:10 http://www.cancerci.com/content/7/1/10
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shown to alter the activity of natural alkaloids [12] for
example, researchers have observed increased cytotoxic
activity of 8-methoxycaffeine compared to the parent
compound [13]. However, the impact of the configura-
tion of methoxy group and its varied effect on the activity
of these AMD alkaloids is a novel and interesting observa-
tion.
Conclusion
A correctly functionalized phenanthridone skeleton
present in natural Amaryllidaceae alkaloids may be a sig-
nificant common element for selectivity against cancer
cells, furthermore, the configuration of the methoxy-side
groups is responsible for higher binding affinity to the tar-
get protein/s thus making for a more efficient anti-cancer
agent.
Methods
Cell cultures
Human T-cell leukemia (Jurkat) cells were obtained from
ATCC, Manassas, VA. These cells were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS) and 10 μM gentamycin (Life Technologies,
Mississauga, ON) in an incubator set at 37°C, 5% CO2
and 95% humidity.
Human nucleated blood cells were isolated from whole
blood taken from a healthy non-smoking male according
to the University of Windsor REB #04-147. The whole
blood sample was collected in a BD Vacutainer™ CPT
(Cell Preparation Tube) obtained from Becton Dickinson,
Franklin Lakes, NJ, and spun at 2900 rpm for 30 min at
25°C. The upper layer consisting of mononuclear cells,
platelets and plasma was collected and maintained with
A. Nuclear Morphology of Jurkat cells treated with AMD5 at 10 μM for either 24 hrs or 48 hrs Figure 3
A. Nuclear Morphology of Jurkat cells treated with AMD5 at 10 μM for either 24 hrs or 48 hrs. Jurkat cells were 
stained with cell-permeable Hoechst 33342 dye to observe apoptotic nuclear morphology. Apoptotic nuclei are brightly 
stained and condensed when compared to healthy nuclei. The control was treated with DMSO solvent. Magnification: 200×. B. 
Annexin-V Binding Assay: Jurkat cells were treated with 10 μM AMD5 for 24 hrs. Jurkat cells were incubated with 
Annexin-V 488 Alexa-Fluor conjugate to observe phosphatidyl-serine flipping from the inner to the outer leaf of the plasma 
membrane. This is a characteristic event of apoptosis that is made visible with use of a fluorescent microscope; cells undergo-
ing apoptosis will have more Annexin-V substrate bound, and thus appear brighter than healthy cells. Magnification: 400×Cancer Cell International 2007, 7:10 http://www.cancerci.com/content/7/1/10
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RPMI 1640 media supplemented with 10% FBS and 10
μM gentamycin (Life Technologies) in the same incubator
as the Jurkat cells.
Cell treatment
Cells were grown and treated with either AMD4 or AMD5
alkaloids at various concentrations and time-points.
AMD4 and AMD5 (99.5% pure) were derived as detailed
by Pettit et al., 1993 [1].
Cellular viability assay
Cells were grown to 70% confluence and treated with
AMD4 and AMD5 at a final concentration of 10 μM. The
cells were then stained with the cell permeable dye
Hoechst 33342 (Molecular Probes, Eugene, OR) at 10 μM
final concentration and incubated for 10 min at 25°C.
Brightly stained, condensed nuclei are characteristic fea-
tures of apoptotic cells, as visualized with a fluorescent
microscope (Leica DM IRB, Germany). Images were cap-
tured at 10× and 40× objectives; the percentage of apop-
totic cells was calculated from the total number of cells
with Microsoft® Excel 6.0 software and pictures were com-
piled using Adobe® Photoshop 7.0 software. A minimum
of 5 fields of at least 100 cells per field was counted. Sta-
tistical significance was determined using STATISTICA®
software.
Annexin-V binding assay
Jurkat cells were treated with 10 μM AMD4 and AMD5 for
24 hours. The Annexin-V binding assay was conducted
A. Caspase-3 Assay: Jurkat cells were treated with 10 μM AMD4 or AMD5 for the early time-points of 3 hrs and 6 hrs Figure 5
A. Caspase-3 Assay: Jurkat cells were treated with 10 μM AMD4 or AMD5 for the early time-points of 3 hrs 
and 6 hrs. Following treatment, Jurkat cells were incubated with DEVD-AFC peptide to detect caspase-3 activity; fluorescence 
was measured at excitation 400 nm and emission 505 nm. Activation of caspase-3 is a common event in cells undergoing apop-
tosis. The level of caspase-3 activity was calculated per microgram of protein and then displayed as a percent increase in fluo-
rescence from caspase-3 activity in untreated cells (control). Values that are statistically significant to p < 0.05 are indicated 
with an asterisk. B. Mito-Casp Assay: Jurkat cells were treated with 10 μM AMD5 for 48 hrs. Following treatment, 
Jurkat cells were incubated with a mitochondrial membrane potential (MMP) sensitive dye, and fluorescence was measured at 
excitation 574 nm and emission at 595 nm. Loss of MMP indicates permeable mitochondria which allows for numerous cyto-
toxic materials to leak into the cytosol, ending in apoptosis. Loss of MMP is represented as a drop in relative fluorescence units 
per 10,000 cells. Values that are statistically significant to p < 0.05 are indicated with an asterisk.
TUNEL Assay: Jurkat cells were treated with AMD5 at 10  μM for 24 hrs Figure 4
TUNEL Assay: Jurkat cells were treated with AMD5 
at 10 μM for 24 hrs. Following treatment, Jurkat cells were 
fixed and immuno-stained with anti-BdrU antibody to 
observe the extent of DNA damage as described in the 
Materials and Methods section. The level of staining indicates 
the degree of DNA damage induced by treatment, where 
more positively stained cells are in the final stages of apopto-
sis. Magnification: 200×Cancer Cell International 2007, 7:10 http://www.cancerci.com/content/7/1/10
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according to the manufacturer's protocol using a kit pur-
chased from Molecular Probes, Eugene, OR. Briefly, cells
were washed with phosphate-buffered saline (PBS) and
re-suspended in Annexin-V binding buffer (10 mM
HEPES/NaOH pH 7.5, 140 mM NaCl, 2.5 mM CaCl2),
containing Annexin-V Alexa Fluor® 488 conjugate (1:50)
for 15 min at 25°C; pictures were taken with a fluorescent
microscope (Leica DM IRB, Germany) at 40× objective
and compiled using Adobe® Photoshop 7.0 software.
TUNEL assay
After treating Jurkat cells with AMD4 and AMD5 at indi-
cated times the TUNEL Assay was performed as per man-
ufacturer's protocol (Molecular Probes, Eugene, OR) and
a previously published method [10], to detect DNA dam-
age. Cells were fixed by suspending them in 70% (v/v)
ethanol and stored at -20°C overnight. The sample was
then incubated with DNA-labeling solution (10 μL reac-
tion buffer, 0.75 μL TdT enzyme, 8 μL BrdUTP, 31.25 μL
of dH2O) for 1 hr at 25°C. Each sample was then exposed
to an antibody solution consisting of 5 μL Alexa Fluor®
488 labeled anti-BrdU antibody with 95 μL rinse solution
and allowed to react for 20 min; pictures were taken at
20× objective using a fluorescent microscope (Leica DM
IRB, Germany).
Caspase-3 assay
The caspase-3 assay was carried out using a previously
published method [11]. Briefly, Jurkat or normal lym-
phocyte cellular lysates were collected and incubated with
the fluorogenic substrate DEVD-AFC (MP Biomedicals,
Aurora, OH) in DEVD buffer (0.1 M HEPES, pH 7.4, 2
mM DTT, 0.1% CHAPS, 1% sucrose) and allowed to incu-
bate at 37°C for 45 min. Fluorescence was measured at
400 nm excitation and 505 nm emission using the Spectra
Max Gemini XS (Molecular Devices, Sunnyvale, CA). Cas-
pase-3 activity was calculated per microgram of protein,
and expressed as a percentage of control activity. Protein
concentration was determined utilizing the BioRad pro-
tein assay reagent (BioRad, Mississauga, ON, Canada)
with bovine serum albumin as a standard. Microsoft®
Excel 6.0 software was used for data representation; statis-
tical significance was determined using STATISTICA® soft-
ware.
Mito-Casp assay
The Mito-Casp assay was performed as per manufacturer's
protocol using a kit purchased from Cell Technology Inc.,
Mountain View, CA. Briefly, cells were treated with either
alkaloid at 10 μM concentration for the desired times and
washed twice in PBS. Cells were re-suspended in PBS
according to protocol and incubated with both MMP dye
and caspase reagent at a 1:30 dilution for 60 min at 37°C
in darkness. Following incubation, the cell pellet was col-
lected and re-suspended in wash buffer; fluorescence was
measured from a 96-well micro-titre plate at 549 nm exci-
tation and 574 nm emission using the Spectra Max
Gemini XS (Molecular Devices, Sunnyvale, CA). Loss of
MMP was presented as a loss in relative fluorescence units
per 10,000 cells. Microsoft® Excel 6.0 software was used
for data representation; statistical significance was deter-
mined using STATISTICA® software.
A. Time Course: Degree of apoptosis in healthy peripheral  mono-nucleated blood cells treated with 10 μM AMD5 for  48 hrs Figure 6
A. Time Course: Degree of apoptosis in healthy 
peripheral mono-nucleated blood cells treated with 
10 μM AMD5 for 48 hrs. Healthy human peripheral mono-
nucleated blood cells were collected & treated for 48 hours 
with 10 μM AMD5. The cells were then stained with cell-
permeable Hoechst 33342 dye to observe apoptotic nuclear 
morphology. Brightly stained and condensed nuclei were 
considered apoptotic, non-bright smooth nuclei were consid-
ered healthy. The degree of apoptosis was calculated by the 
number of apoptotic cells counted over the total number of 
cells visible displayed as a percentage. A minimum of 5 fields 
with at least 100 cells per field were counted and tabulated 
using Microsoft Excel software; values that are statistically 
significant to p < 0.05 are indicated with an asterisk. B. 
Nuclear Morphology: Healthy human peripheral 
mono-nucleated blood cells were collected & treated 
with 10 μM of AMD5 for 48 hrs. Cells were stained with 
cell permeable Hoechst 33342 dye to observe apoptotic 
nuclear morphology. Apoptotic nuclei are brightly stained 
and condensed when compared to healthy nuclei. The con-
trol was treated with DMSO solvent. Magnification: 200×.Publish with BioMed Central    and   every 
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